Spruce Biosciences Stock Forecast
NASDAQ: SPRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 3:17 PM ET
SPRB analyst consensus
Consensus (9 analysts)
strong_buy
Avg. price target
$148.00+237.13%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Spruce Biosciences (2026-10-08), 9 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $148.00, with a high estimate of $230.00 and a low estimate of $104.00. The average target implies upside of 237.1% from the current price of $43.90.
The spread between the highest and lowest targets is 121.2%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SPRB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 11% |
| Buy | 8 | 89% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $104.00 | +136.90% |
| Average target | $148.00 | +237.13% |
| High target | $230.00 | +423.92% |